CSL names AWS as its principal cloud and AI provider for drug research.
Amazon announced that its cloud computing division, Amazon Web Services (AWS), has been selected by Australian biopharmaceutical giant CSL Limited as its principal cloud and artificial intelligence provider. The collaboration aims to accelerate CSL's drug research pipeline and clinical development programs.
Under the agreement, CSL will deploy AWS cloud infrastructure and AI tools across its research operations. The companies did not disclose the financial terms, total contract value, or duration of the partnership.
Following the announcement on September 29, 2026, shares of CSL traded at 181.90 Australian dollars on the Australian Securities Exchange.
Share prices can rise and fall. Past performance does not guarantee future results. This article is news, not investment advice.
Newsletter
Markets in your inbox, weekly
Latin America-focused analysis, investment themes and the week in finance.
Keep reading